Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06247839 · ClinicalTrials.gov registry record · Phase 3

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

A Phase 3 study of Major Depressive Disorder, sponsored by Sharmin Ghaznavi.

Recruiting
Registry status
Phase 3
Development phase
20
Enrollment target
1
Study location

NCT06247839: Recruiting Phase 3 study of Major Depressive Disorder, sponsored by Sharmin Ghaznavi.

NCT06247839 is a Phase 3 study of Major Depressive Disorder that is actively recruiting participants, run by Sharmin Ghaznavi. The registered enrollment target is 20 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06247839, a Phase 3 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Sharmin Ghaznavi.

RECRUITING
Registry status
Phase 3
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.

Primary Outcome

A transdiagnostic state measure of rumination over the previous two weeks consisting of 9 items on a 5 point Likert scale from 0 (Never/Rarely) to 4 (All The Time).

Conditions Studied

Major Depressive Disorder

Interventions

  • DRUG Psilocybin

Study Locations (1)

Massachusetts

  • Athinoula A. Martinos Center for Biomedical Imaging - Charlestown

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-09-10
Est. Completion 2026-06-30
Phase Phase 3
Sharmin Ghaznavi

1 total trials

What NCT06247839 shows while recruiting

NCT06247839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.

NCT06247839 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06247839 about?

NCT06247839 is a clinical study titled "The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder". This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.

What is the current status of trial NCT06247839?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2024-09-10. Estimated completion is 2026-06-30.

What conditions does trial NCT06247839 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT06247839?

The interventions under investigation include: Psilocybin (DRUG).

Who is sponsoring clinical trial NCT06247839?

This trial is sponsored by Sharmin Ghaznavi, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06247839 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06247839's enrollment target sits among peer trials

20 243rd of 282 higher than 34 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06247839

Source: ClinicalTrials.gov NCT06247839, the US trial registry maintained by the National Library of Medicine. NCT06247839 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.